Kalvista Pharmaceuticals Inc. has shared new data on EKTERLY® (sebetralstat), an oral on-demand treatment for acute attacks of hereditary angioedema $(HAE)$ in patients aged 12 years and older. EKTERLY® is currently approved in the US, UK, EU, Switzerland, and Australia. The presentation highlights that EKTERLY® is the first and only oral on-demand therapy for HAE, providing an alternative to injectable or intravenous treatments, which are often associated with complex logistics and underutilization. Data from open-label extension trials show a median time to treatment initiation of 10 minutes and a median time to end of attack progression of 19.8 minutes. A total of 2,753 attacks, including 59 laryngeal and 1,172 abdominal attacks, were treated as of the latest data cutoff. No reports of difficulty swallowing were noted in laryngeal attacks. Among patients switching from injectable treatments, 84% reported satisfaction with sebetralstat. The presentation also notes the treatment of 585 attacks in patients on long-term prophylaxis and 561 breakthrough attacks. You can access the full presentation through the link below.